AI assistant
Sending…
10x Genomics, Inc. — Director's Dealing 2021
Oct 12, 2021
31830_dirs_2021-10-12_ee2bd92b-4957-4b19-9ac4-d61657b1928a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-10-07
Reporting Person: STUELPNAGEL JOHN R (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-07 | Class A Common Stock | S | 5000 | $150.1798 | Disposed | 366616 | Direct |
Footnotes
F1: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
More from 10x Genomics, Inc.
Regulatory Filings
2026
May 7
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 25
Major Shareholding Notification
2026
Mar 25
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 25